UPTRAVI® (selexipag)—Adverse Reactions in the GRIPHON Trial1

Adverse Reactions Occurring More Frequently on UPTRAVI Compared to Placebo by ≥3%

UPTRAVI Versus Placebo Adverse Events Occurences
  • Hyperthyroidism was observed in 1% (n=8) of patients on UPTRAVI and in none of the patients on placebo
  • Median duration of exposure to UPTRAVI was 1.4 years
  • These adverse reactions were more frequent during the dose titration phase